Ani Pharmaceuticals (ANIP) EBT Margin (2011 - 2026)
Ani Pharmaceuticals (ANIP) posted EBT Margin of 16.94% for Q1 2026, up 32.94% sequentially from 12.74% in Q4 2025, and up 680.0% YoY from 2.17% in Q1 2025.
Ani Pharmaceuticals (ANIP) EBT Margin (2011 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported EBT Margin for 16 years, with the latest figure at 16.94% in Q1 2026.
- Quarterly EBT Margin rose 680.0% year-over-year to 16.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.56% (up 1665.0% YoY) and the FY2025 annual result came in at 10.84%, up 1446.0% from the prior year.
- EBT Margin rose to 16.94% in Q1 2026 per ANIP's latest filing, from 12.74% in the prior quarter.
- Over five years, EBT Margin peaked at 18.43% in Q1 2024 and troughed at 40.17% in Q1 2022.
- A 5-year average of 1.32% and a median of 2.03% in 2023 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 4452 bps in 2022, down 4085 bps in 2022.
- Over 5 years, EBT Margin stood at 6.12% in 2022, then soared by 112 bps to 0.72% in 2023, then plunged by 1104 bps to 7.22% in 2024, then jumped by 276 bps to 12.74% in 2025, then jumped by 33 bps to 16.94% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 16.94%, 12.74%, and 14.84% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 13.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.94% |
| Mar 31, 2026 | 16.94% |
| Dec 31, 2025 | 12.74% |
| Sep 30, 2025 | 14.84% |
| Jun 30, 2025 | 4.98% |
| Mar 31, 2025 | 10.14% |
| Dec 31, 2024 | -7.22% |
| Sep 30, 2024 | -21.23% |
| Jun 30, 2024 | -1.66% |
| Mar 31, 2024 | 18.43% |
| Dec 31, 2023 | 0.72% |
| Sep 30, 2023 | 8.73% |
| Jun 30, 2023 | 4.50% |
| Mar 31, 2023 | 2.03% |
| Dec 31, 2022 | -6.12% |
| Sep 30, 2022 | -14.58% |
| Jun 30, 2022 | -25.48% |
| Mar 31, 2022 | -40.17% |
| Dec 31, 2021 | -50.64% |
| Sep 30, 2021 | -13.64% |